<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077805</url>
  </required_header>
  <id_info>
    <org_study_id>XRP4563H_4001</org_study_id>
    <nct_id>NCT00077805</nct_id>
  </id_info>
  <brief_title>PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)</brief_title>
  <official_title>An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
        -  To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared&#xD;
           to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following&#xD;
           acute ischemic stroke.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To compare the incidence of VTE between the 2 treatment groups at 30, 60, and 90 days&#xD;
           from the time of randomization&#xD;
&#xD;
        -  To compare neurologic outcomes between the 2 treatment groups, including incidence of&#xD;
           stroke recurrence, rate of stroke progression, and patient functional status, during the&#xD;
           10 ± 4 days of treatment, and after 30, 60, and 90 days from the time of randomization&#xD;
&#xD;
        -  To evaluate the safety of using enoxaparin compared to UFH for VTE prevention in&#xD;
           patients following acute ischemic stroke&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative occurrence of VTE events (deep-vein thrombosis, pulmonary embolism)</measure>
    <time_frame>10 ± 4 days following acute ischemic stroke</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative VTE events</measure>
    <time_frame>at 30-day, 60-day and 90-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke recurrence, stroke progression, National Institute of Health Stroke Scale (NIHSS) scores</measure>
    <time_frame>during treatment and follow-up periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (MRS) scores</measure>
    <time_frame>at 30-day and 90-day follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major &amp; minor hemorrhages</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events (TEAE), serious adverse events (SAE), all-cause mortality</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <condition>Acute Ischemic Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Acute ischemic stroke, any territory, with an appropriate neuroradiologic study (head&#xD;
             CT scan or brain MRI scan) providing results consistent with non hemorrhagic stroke&#xD;
&#xD;
          -  Onset of symptoms of qualifying stroke within 48 hours prior to randomization. In&#xD;
             patients receiving thrombolytic therapy for the acute stroke, such as tissue-type&#xD;
             plasminogen activator (tPA), administration of study drug may not start until at least&#xD;
             24 hours after completion of thrombolytic therapy&#xD;
&#xD;
          -  Significant motor impairment of the leg, as indicated by a NIHSS score ≥2 on item 6&#xD;
&#xD;
          -  Inability to walk without assistance&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Females who are pregnant, breast-feeding, or of childbearing potential and not using&#xD;
             medically acceptable and effective contraception&#xD;
&#xD;
          -  Clinical evidence of VTE at screening&#xD;
&#xD;
          -  Any evidence of active bleeding on the basis of clinical judgment&#xD;
&#xD;
          -  Prior history of intracranial hemorrhage (including that at screening)&#xD;
&#xD;
          -  Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours&#xD;
&#xD;
          -  Thrombolytic therapy (e.g., tPA) or intra-arterial thrombolytic therapy within the&#xD;
             preceding 24 hours.Thrombolytic therapy is permitted for treatment of the acute stroke&#xD;
             but must have been completed 24 hours prior to randomization.&#xD;
&#xD;
          -  Comatose at screening (NIHSS score ≥2 on item 1a)&#xD;
&#xD;
          -  Known or suspected cerebral aneurysm or arteriovenous malformation&#xD;
&#xD;
          -  Confirmed malignancy that may pose an increased risk for bleeding or otherwise&#xD;
             compromise follow-up or outcome assessment (e.g., lung cancer)&#xD;
&#xD;
          -  Impaired hemostasis, i.e., known or suspected coagulopathy (acquired or inherited);&#xD;
             baseline platelet count &lt;100,000/mm3; aPTT 1.5 X the laboratory upper limit of normal;&#xD;
             or international normalized ratio(INR) &gt;1.5&#xD;
&#xD;
          -  Major surgery or recent major trauma within the previous 3 months&#xD;
&#xD;
          -  Anticipated need for full-dose treatment with therapeutic levels of an anticoagulant&#xD;
             (LMWH, UFH, oral anticoagulant), e.g., for cardiogenic source of embolism or&#xD;
             dissection&#xD;
&#xD;
          -  Treatment with a LMWH or UFH at prophylactic dose for more than 48 hours prior to&#xD;
             randomization(patients receiving LMWH or UFH less than 48 hours prior to randomization&#xD;
             may be randomized)&#xD;
&#xD;
          -  Allergy to heparin or enoxaparin sodium, or known hypersensitivity to heparin,&#xD;
             enoxaparin, or pork products&#xD;
&#xD;
          -  History of heparin or enoxaparin induced thrombocytopenia and/or thrombosis&#xD;
             (heparin-induced thrombocytopenia [HIT], heparin-associated thrombocytopenia [HAT], or&#xD;
             heparin-induced thrombotic thrombocytopenia syndrome [HITTS])&#xD;
&#xD;
          -  History of hypersensitivity to iodinated contrast media and/or iodine&#xD;
&#xD;
          -  Bacterial endocarditis&#xD;
&#xD;
          -  Prosthetic heart valve&#xD;
&#xD;
          -  Known or suspected severe anemia (Hg &lt;10.0 g/dL)&#xD;
&#xD;
          -  Uncontrolled arterial hypertension (systolic blood pressure [BP] &gt;180 mmHg or&#xD;
             diastolic BP &gt;100 mmHg) at the time of randomization or clinical hypertensive urgency&#xD;
&#xD;
          -  Any other clinically relevant serious diseases, including severe liver disease or&#xD;
             renal failure [creatinine clearance &lt;30 mL/min on at least two occasions].&#xD;
&#xD;
          -  Treatment with other investigational agents or devices within the previous 30 days,&#xD;
             planned use of other investigational drugs or devices, or previous enrollment in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Sagnard</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
  </removed_countries>
  <results_reference>
    <citation>Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O'Riordan W, Pineo GF; PREVAIL Investigators. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke. 2009 Nov;40(11):3532-40. doi: 10.1161/STROKEAHA.109.555003. Epub 2009 Aug 20.</citation>
    <PMID>19696423</PMID>
  </results_reference>
  <results_reference>
    <citation>Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O'Riordan W, Pineo GF; PREVAIL Investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007 Apr 21;369(9570):1347-1355. doi: 10.1016/S0140-6736(07)60633-3.</citation>
    <PMID>17448820</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>February 12, 2004</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Enoxaparin sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

